Tidal Investments LLC Has $14.89 Million Stake in Halozyme Therapeutics, Inc. $HALO

Key Points

• Tidal Investments increased its Halozyme Therapeutics stake by 13.5% in the second quarter, owning 190,305 shares valued at approximately $14.9 million. Institutional investors collectively own 97.79% of the company.
• Halozyme reported a strong quarter, with earnings of $2.28 per share versus the $1.79 consensus estimate and revenue of $481 million, up 47.7% year over year. Shares opened at $107, near the company’s 52-week high.
• Analyst sentiment remains favorable, with nine Buy ratings and a consensus “Moderate Buy” rating, although the average price target of $91.20 is below the current share price. Insiders have sold 32,478 shares worth about $3.1 million over the past three months.

Tidal Investments LLC increased its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 13.5% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 190,305 shares of the biopharmaceutical company's stock after purchasing an additional 22,707 shares during the period. Tidal Investments LLC owned approximately 0.17% of Halozyme Therapeutics worth $14,895,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also added to or reduced their stakes in the company. Measured Wealth Private Client Group LLC increased its position in Halozyme Therapeutics by 51.5% during the 4th quarter. Measured Wealth Private Client Group LLC now owns 365 shares of the biopharmaceutical company's stock worth $25,000 after buying an additional 124 shares during the period. Abel Hall LLC boosted its position in shares of Halozyme Therapeutics by 4.2% in the fourth quarter. Abel Hall LLC now owns 3,216 shares of the biopharmaceutical company's stock valued at $216,000 after acquiring an additional 129 shares during the period. StoneX Group Inc. grew its stake in shares of Halozyme Therapeutics by 3.8% in the fourth quarter. StoneX Group Inc. now owns 3,650 shares of the biopharmaceutical company's stock valued at $246,000 after acquiring an additional 132 shares in the last quarter. Twin Capital Management Inc. grew its stake in shares of Halozyme Therapeutics by 1.4% in the first quarter. Twin Capital Management Inc. now owns 11,422 shares of the biopharmaceutical company's stock valued at $738,000 after acquiring an additional 161 shares in the last quarter. Finally, Coldstream Capital Management Inc. increased its position in Halozyme Therapeutics by 1.9% during the third quarter. Coldstream Capital Management Inc. now owns 8,914 shares of the biopharmaceutical company's stock worth $654,000 after acquiring an additional 165 shares during the period. 97.79% of the stock is currently owned by institutional investors.

Halozyme Therapeutics Trading Down 0.4%

Shares of HALO opened at $107.00 on Friday. The company has a debt-to-equity ratio of 13.50, a quick ratio of 2.31 and a current ratio of 2.71. Halozyme Therapeutics, Inc. has a 52-week low of $61.22 and a 52-week high of $111.15. The firm has a market cap of $12.14 billion, a price-to-earnings ratio of 31.94, a PEG ratio of 0.42 and a beta of 0.88. The business's fifty day moving average is $93.18 and its 200-day moving average is $76.75.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share for the quarter, beating the consensus estimate of $1.79 by $0.49. The business had revenue of $481.00 million for the quarter, compared to analyst estimates of $402.28 million. Halozyme Therapeutics had a return on equity of 260.98% and a net margin of 24.86%.Halozyme Therapeutics's revenue was up 47.7% compared to the same quarter last year. During the same period last year, the firm posted $1.54 earnings per share. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. Equities analysts anticipate that Halozyme Therapeutics, Inc. will post 7.98 EPS for the current fiscal year.

Insider Activity at Halozyme Therapeutics

In related news, Director Bernadette Connaughton sold 1,626 shares of the company's stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $102.80, for a total transaction of $167,152.80. Following the completion of the transaction, the director directly owned 40,418 shares in the company, valued at $4,154,970.40. This represents a 3.87% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mahesh Krishnan sold 7,304 shares of the stock in a transaction that occurred on Monday, June 29th. The shares were sold at an average price of $75.00, for a total transaction of $547,800.00. Following the completion of the transaction, the director directly owned 14,462 shares of the company's stock, valued at approximately $1,084,650. The trade was a 33.56% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 32,478 shares of company stock valued at $3,076,604. 2.50% of the stock is owned by insiders.

Analysts Set New Price Targets

HALO has been the subject of a number of recent research reports. Leerink Partners raised shares of Halozyme Therapeutics from a "market perform" rating to an "outperform" rating and boosted their price objective for the company from $83.00 to $110.00 in a report on Friday, August 7th. Citizens Jmp raised their target price on shares of Halozyme Therapeutics from $92.00 to $93.00 and gave the stock a "market outperform" rating in a report on Friday, August 7th. Weiss Ratings upgraded Halozyme Therapeutics from a "buy (b-)" rating to a "buy (b)" rating in a research note on Monday, August 31st. Wall Street Zen upgraded Halozyme Therapeutics from a "buy" rating to a "strong-buy" rating in a research note on Saturday, August 8th. Finally, Wells Fargo & Company lifted their price objective on Halozyme Therapeutics from $75.00 to $95.00 and gave the company an "equal weight" rating in a report on Friday, August 7th. Nine research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $91.20.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing drug-delivery technologies that improve the administration of medicines. The company's primary technology is ENHANZE, which uses recombinant human hyaluronidase PH20 to facilitate the subcutaneous delivery of certain biologic and other injectable therapies that might otherwise require intravenous infusion.

Halozyme provides ENHANZE technology to pharmaceutical and biotechnology partners through licensing and collaboration agreements.

Want to see what other hedge funds are holding HALO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.